The study will enrol around 100 participants.

Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track ...

In an analysis of therapeutic interventions following the failure of chimeric antigen receptor (CAR) T-cell therapy, Rahul ...

Researchers have advanced DTP3, a first-in-class drug targeting the GADD45β/MKK7 complex, into Phase 2 trials for multiple ...

This reinforces the need for a CV assessment and surveillance before, during, and after the therapy, a researcher says.

The U.S. Food and Drug Administration (FDA) recently approved the use of Darzalex Faspro (daratumumab and hyaluronidase-fihj) in combination with Velcade (bortezomib), Revlimid (l ...

Sponsored FOY Multiple Myeloma Patient Has ‘Vision’ for Future Benjamin Diamond, M.D., a hematologist-oncologist who specializes in multiple myeloma at Sylvester Comprehensive Cancer Center, explains ...

"Therapeutic innovations like elranatamab achieve a lasting response in 61% of patients with multiple myeloma and complete remission in 30%," said Dr María Victoria Mateos, a consultant physician in ...

Palliative care that recognizes patient goals and values is essential, starting at diagnos ...

Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology ...

Nearly everyone with multiple myeloma relapses. That doesn’t make it easy. A cancer diagnosis is traumatic, especially when the cancer is treatable, but not curable. In multiple myeloma, the disease ...

There may be discrepancies in the types of information patients want and the information they receive when multiple myeloma treatment decisions are made, a recent study found. There may be ...